Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922041 | 0.91 | MEN1 (0.49) | KMT2AMEN1KDM4CL3MBTL1RAB9A | |
| SCHEMBL8854257 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL6906651 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL9527531 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL18364935 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL15151056 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL2913896 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL7057539 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL8498418 | 0.89 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL6708639 | 0.88 | MEN1 (0.46) | KMT2AMEN1KDM4CL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502172-A | Nucleoside prodrugs and related uses thereof | 爱默蕾大学 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | KMT2A 3065/4885MEN1 4325/4885KDM4C 3438/4885 |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | KMT2A 3065/4885MEN1 4325/4885KDM4C 3438/4885 |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | PNPO, GSTO1, CYP2C18 | KMT2A 3065/4885MEN1 4325/4885KDM4C 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.